What is it about?
This study shows that the protease inhibitor nafamostat, which has been approved for treatment of pancreatitis in Japan, inhibits SARS-CoV-2 infection of lung cells. Our previous work indicates that inhibition is due to blockade of the cellular protease TMPRSS2, which activates the spike protein of SARS-CoV-2
Why is it important?
The results suggest that Nafamostat should be considered for COVID-19 treatment
Read the Original
This page is a summary of: Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19, Antimicrobial Agents and Chemotherapy, April 2020, ASM Journals, DOI: 10.1128/aac.00754-20.
You can read the full text:
The following have contributed to this page